Why Attend
Europe is a powerhouse of research, but has been struggling to keep pace with development in the US. Get multiple perspectives in panels how to attract investment from C-suite executives and investors themselves, and explore European regulatory and reimbursement challenges for the cell therapy field. This is your unique opportunity to:
- Meet with 200+ of Europe’s leading innovators and investors, to drive partnership and collaboration and drive adoptive cell therapies to the market
- Address durability, reduce exhaustion, and build in optimal approaches for targeting antigen heterogeneity to hit the tumour microenvironment
- Explore genome-editing, iPSC-derived approaches and management strategies for chromosomal abnormalities and translocations for allogeneic cell therapy development
- Establish robust, scalable and flexible vein-to-vein processes to enhance just in time delivery of cell therapies
2022 Industry Leading Speakers

Andrea Braun- Scherhag

Ann Ager

Bakul Gupta
Dr Bakul Gupta is the CEO and Co-founder of ImmTune Therapies, a preclinical stage cell therapy biotech which is developing safe, scalable and affordable in vivo cell therapies. The company is leveraging its unique platform to effectively deliver genetic cargoes directly to targeted cells, and applying it across different indications in cell and gene therapies.
Bakul founded the company in 2019, along with her business partner, Dr George Tetley after a 6-month long research into the challenges faced by current cell and gene therapy companies. She holds a PhD and BSc in Nanotechnology and Chemistry from the UNSW Australia, and finished her postdoctoral training with Prof. Molly Stevens at Imperial College London before starting ImmTune Therapies.
She has over 10 years of experience in designing nano- and bio-materials for a diverse set of biomedical applications and has previous experience in commercialisation of medical devices. She was recently listed as the Top 30 biotech entrepreneurs to watch as part of a report produced by BioBeat.

Behnam Sadeghi
Behnam Sadeghi graduated as medical doctor (MD) in 1995. Dr Sadeghi did his PhD in transplantation Immunology in 2009 at Karolinska Institute, Stockholm, Sweden. Since then, Dr Sadeghi’s research concentrated in the field of cell therapy and regenerative medicine both in clinical practice and experimental models. Dr Sadeghi established and applied decidua stromal cells (DSC) for the treatment of steroid refractory GVHD, ARDS and other acute inflammatory disorders in man. Other cell therapy modalities including bone marrow, adipose derived mesenchymal stromal cells (BM, Ad-MSC) are among his research interest. Currently, Dr Sadeghi is head of Translational Cell therapy Research group (TCR) at the department of CLINTEC, Karolinska Institute, Stockholm, Sweden.

Benjamin Rengstl
Dr. Benjamin Rengstl is a trained physician and biochemist. Since 2009, he is exploring the potential of the immune system to combat cancer and infectious diseases. Between 2014 and 2016, he received his approbation as well as a PhD and a MD degree from the University of Frankfurt, Germany. During his postdoctoral training, he developed chimeric antigen receptor (CAR)-engineered T-cell therapies against lymphomas and got trained in clinical pathology. In 2017, he joined BioNTech SE located in Mainz to develop a clinical CAR-T cell candidate for treatment of solid tumors. To improve CAR-T cell therapy, his team pioneered an in vivo expansion concept based on a liposomally formulated RNA vaccine for systemic delivery of CAR antigen (CAR T-cell Amplifying RNA Vaccine, CARVac). A FIH clinical trial assessing BioNTech´s novel CLDN6-specific CAR in combination with CARVac is currently ongoing. Furthermore, he is leading multiple programs to develop next generation cell- and RNA-based immunotherapies and further takes technology agnostic approaches to create new strategies for controlled modulation of the immune system.

Bernd Eschgfäller

Carole Sansoz

Chris Baldwin

Dan Shelly

Dora Hammerl

Etienne Jousseaume

Frédéric Desdouits

Gil Beyen

Hélène Negre

Hemant Dhamne

Ineke Jonker-Hoogerkamp

Inge Jedema

Inna Menkova

Joachim Koch

Joël Plumas

Juliana Dias Alves Pinto

Luca Gattinoni

Magdalena Krol

Michael Hudecek

Marcel Zwaal

Michael Traxlmayr

Mikhail Steklov

Olivier Negre

Paul Ibbett

Pedro Correa de Sampaio

Rebecca Street-Howard

Robert Igarashi

Sangho Lim

Sarah Tettamanti

Stuart Curbishly

Sven Kili

Troels Jordansen
OUR CELL THERAPY COMMUNITY

Venue
Venue tbc, fill out the agenda form to register your interest and find out first when we announce the location!
2022 Agenda
Be the first to download our 2022 agenda:
Access the Full Event Schedule
TESTIMONIALS

2022 Event Partners
Barrington James
Website: https://barringtonjames.com/
Please visit our website for more information.2022 Expertise Partners
Miltenyi Biotec
Website: https://www.miltenyibiotec.com/GB-en/
Please visit our website for more information.2022 Exhibitors
FENIX - CELLTELIGENCE
Website: https://celltelligence.com/
Please visit our website for more information.Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
2022 Media Partners
Gene Therapy Net
Website: http://www.genetherapynet.com/
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network for the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
Partner With Us
Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
To discuss your objectives and partnership opportunities please contact [email protected].
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase in
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.